Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
61,437.61 +598.25 (+0.98%) CMC Crypto 200
1,276.02 -7.81 (-0.61%)
ATXS Oct 2024 17.500 call
| Previous close | 0.2100 |
| Open | 2.3000 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 17.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.2100 - 2.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 04, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria’s common stock on June 3, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
Business WireAstria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
BOSTON, May 30, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6th at 10:00am ET in New York, NY.
Business WireAstria Therapeutics to Present at Upcoming Eastern Allergy Conference
BOSTON, May 24, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.
